Literature DB >> 9558398

6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas.

M Merup1, T C Moreno, M Heyman, K Rönnberg, D Grandér, R Detlofsson, O Rasool, Y Liu, S Söderhäll, G Juliusson, G Gahrton, S Einhorn.   

Abstract

Deletions on the long arm of chromosome 6 are frequently found in acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphomas (NHL). We have used polymerase chain reaction analysis to study loss of heterozygosity of 16 microsatellite markers on chromosome 6 in 74 ALL and 54 NHL patients. Our results show that deletions of 6q in ALL are more frequent than what has been reported in previous studies, occurring in at least 32% of the patients. The corresponding figure for NHL patients is 7%. Our results define a region of minimal deletion in ALL of less than 500 kb between markers D6S1709 and D6S434. The common region of deletion in NHL is located telomeric of this region. Thus, two different tumor suppressor genes on chromosome 6q seem to be relevant for the development of lymphoid malignancies.

Entities:  

Mesh:

Year:  1998        PMID: 9558398

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1.

Authors:  Satoko Arai; Toru Miyazaki
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

Review 2.  Genetic alterations in chronic lymphocytic leukaemia.

Authors:  Llorenç Coll-Mulet; Joan Gil
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

3.  PDCD2 controls hematopoietic stem cell differentiation during development.

Authors:  Joseph Kramer; Celine J Granier; Stephani Davis; Katherine Piso; Jane Hand; Arnold B Rabson; Hatem E Sabaawy
Journal:  Stem Cells Dev       Date:  2012-08-16       Impact factor: 3.272

Review 4.  BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint.

Authors:  Srividya Swaminathan; Cihangir Duy; Markus Müschen
Journal:  Trends Immunol       Date:  2013-12-10       Impact factor: 16.687

Review 5.  T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

Authors:  Emma Kroeze; Jan L C Loeffen; Vera M Poort; Jules P P Meijerink
Journal:  Blood Adv       Date:  2020-07-28

6.  Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations.

Authors:  L L Siu; K F Wong; J K Chan; Y L Kwong
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

7.  The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.

Authors:  Beverly W Baron; John Anastasi; Michael J Thirman; Yoichi Furukawa; Scott Fears; David C Kim; Federico Simone; Mark Birkenbach; Anthony Montag; Annamma Sadhu; Nancy Zeleznik-Le; Timothy W McKeithan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

8.  A major lung cancer susceptibility locus maps to chromosome 6q23-25.

Authors:  J E Bailey-Wilson; C I Amos; S M Pinney; G M Petersen; M de Andrade; J S Wiest; P Fain; A G Schwartz; M You; W Franklin; C Klein; A Gazdar; H Rothschild; D Mandal; T Coons; J Slusser; J Lee; C Gaba; E Kupert; A Perez; X Zhou; D Zeng; Q Liu; Q Zhang; D Seminara; J Minna; M W Anderson
Journal:  Am J Hum Genet       Date:  2004-07-21       Impact factor: 11.025

9.  Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.

Authors:  Beverly W Baron; Nancy Zeleznik-Le; Miriam J Baron; Catherine Theisler; Dezheng Huo; Matthew D Krasowski; Michael J Thirman; Rebecca M Baron; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-27       Impact factor: 11.205

10.  PDCD2 knockdown inhibits erythroid but not megakaryocytic lineage differentiation of human hematopoietic stem/progenitor cells.

Authors:  Natalia A Kokorina; Celine J Granier; Stanislav O Zakharkin; Stephani Davis; Arnold B Rabson; Hatem E Sabaawy
Journal:  Exp Hematol       Date:  2012-08-22       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.